{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:35:53Z","timestamp":1781195753938,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008551","name":"Fondation M\u00e9rieux","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ymthe.2024.12.013","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T19:22:26Z","timestamp":1734031346000},"page":"499-513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Self-amplifying mRNA vaccines protect elderly BALB\/c mice against a lethal respiratory syncytial virus infection"],"prefix":"10.1016","volume":"33","author":[{"given":"Lulu","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhua","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9044-8153","authenticated-orcid":false,"given":"Gary","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.12.013_bib1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/rmv.1704","article-title":"Respiratory syncytial virus infection and immunity","volume":"22","author":"Gonz\u00e1lez","year":"2012","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ymthe.2024.12.013_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1067\/S0022-3476(03)00508-0","article-title":"Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection","volume":"143","author":"Welliver","year":"2003","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ymthe.2024.12.013_bib3","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am. J. Dis. Child."},{"key":"10.1016\/j.ymthe.2024.12.013_bib4","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1186\/cc4984","article-title":"Extrapulmonary manifestations of severe respiratory syncytial virus infection--a systematic review","volume":"10","author":"Eisenhut","year":"2006","journal-title":"Crit. Care"},{"key":"10.1016\/j.ymthe.2024.12.013_bib5","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.12.013_bib6","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1038\/s41467-024-47757-9","article-title":"Deviations in RSV epidemiological patterns and population structures in the United States following the COVID-19 pandemic","volume":"15","author":"Rios-Guzman","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.12.013_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1086\/509930","article-title":"Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients","volume":"44","author":"Boeckh","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ymthe.2024.12.013_bib8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fcimb.2019.00275","article-title":"Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus","volume":"9","author":"Tian","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ymthe.2024.12.013_bib9","first-page":"Cd009417","article-title":"Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection","volume":"8","author":"Sanders","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymthe.2024.12.013_bib10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/INF.0000000000000240","article-title":"Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness","volume":"33","author":"Ramilo","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.ymthe.2024.12.013_bib11","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-2308","article-title":"Monoclonal Antibody Treatment of RSV Bronchiolitis in Young Infants: A Randomized Trial","volume":"143","author":"Alansari","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2024.12.013_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.12.013_bib13","first-page":"138","article-title":"Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development","volume":"12","author":"Schmidt","year":"2023","journal-title":"Pathogens (Basel, Switzerland)"},{"key":"10.1016\/j.ymthe.2024.12.013_bib14","unstructured":"ARTURUS (2023). Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics\u2019 ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults. http:\/\/arcturusrx.com."},{"key":"10.1016\/j.ymthe.2024.12.013_bib15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1473-3099(23)00650-3","article-title":"Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2024.12.013_bib16","unstructured":"FDA (2023). Arexvy. https:\/\/www.fda.gov\/vaccines-blood-biologics\/arexvy."},{"key":"10.1016\/j.ymthe.2024.12.013_bib17","unstructured":"FDA (2023). Arbysvo. https:\/\/www.fda.gov\/vaccines-blood-biologics\/abrysvo."},{"key":"10.1016\/j.ymthe.2024.12.013_bib18","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2024.12.013_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12026-007-0071-6","article-title":"Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease","volume":"39","author":"Castilow","year":"2007","journal-title":"Immunol. Res."},{"key":"10.1016\/j.ymthe.2024.12.013_bib20","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1099\/0022-1317-66-10-2111","article-title":"Two distinct subtypes of human respiratory syncytial virus","volume":"66","author":"Mufson","year":"1985","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2024.12.013_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12016-013-8368-9","article-title":"Respiratory syncytial virus--a comprehensive review","volume":"45","author":"Borchers","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.ymthe.2024.12.013_bib22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41541-022-00487-9","article-title":"Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle","volume":"7","author":"Rainho-Tomko","year":"2022","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2024.12.013_bib23","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.12.013_bib24","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.12.013_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.antiviral.2018.11.015","article-title":"Establishment of a lethal aged mouse model of human respiratory syncytial virus infection","volume":"161","author":"Zhang","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ymthe.2024.12.013_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105880","article-title":"Inhalation of 2, 4-di-tert-butylphenol-Loaded micelles suppresses respiratory syncytial virus infection in mice","volume":"226","author":"Guo","year":"2024","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ymthe.2024.12.013_bib27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.12.013_bib28","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nsmb.3267","article-title":"Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV","volume":"23","author":"Joyce","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ymthe.2024.12.013_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1955812","article-title":"Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein","volume":"13","author":"Harshbarger","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.ymthe.2024.12.013_bib30","doi-asserted-by":"crossref","first-page":"L148","DOI":"10.1152\/ajplung.00065.2011","article-title":"Animal models of human respiratory syncytial virus disease","volume":"301","author":"Bem","year":"2011","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ymthe.2024.12.013_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/2040206618770518","article-title":"Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus","volume":"26","author":"Boukhvalova","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ymthe.2024.12.013_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/iai.42.1.81-87.1983","article-title":"Mechanisms of immunity to respiratory syncytial virus in cotton rats","volume":"42","author":"Prince","year":"1983","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2024.12.013_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.12.013_bib34","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1128\/jvi.55.3.517-520.1985","article-title":"Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats","volume":"55","author":"Prince","year":"1985","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2024.12.013_bib35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-020-0163-z","article-title":"Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection","volume":"5","author":"Espeseth","year":"2020","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2024.12.013_bib36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/vim.2017.0147","article-title":"Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field","volume":"31","author":"Kulkarni","year":"2018","journal-title":"Viral Immunol."},{"key":"10.1016\/j.ymthe.2024.12.013_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chom.2021.11.006","article-title":"Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates","volume":"30","author":"Zohar","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2024.12.013_bib38","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1016\/j.cell.2022.11.012","article-title":"Antibody effector functions are associated with protection from respiratory syncytial virus","volume":"185","author":"Bartsch","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2024.12.013_bib39","article-title":"Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines","volume":"12","author":"Topalidou","year":"2023","journal-title":"Pathogens (Basel, Switzerland)"},{"key":"10.1016\/j.ymthe.2024.12.013_bib40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.virol.2009.02.027","article-title":"The 5'UTR-specific mutation in VEEV TC-83 genome has a strong effect on RNA replication and subgenomic RNA synthesis, but not on translation of the encoded proteins","volume":"387","author":"Kulasegaran-Shylini","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2024.12.013_bib41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0023677219883319","article-title":"Defining body-weight reduction as a humane endpoint: a critical appraisal","volume":"54","author":"Talbot","year":"2020","journal-title":"Lab. Anim."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624008128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624008128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:52:32Z","timestamp":1770252752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624008128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1525001624008128"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.013","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Self-amplifying mRNA vaccines protect elderly BALB\/c mice against a lethal respiratory syncytial virus infection","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}